Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5237551 | 0.98 | KDM4E (0.44) | HTR2CNPC1RAB9ACHRNB2CHRNA4 | |
| SCHEMBL5088 | 0.93 | HTR2C (0.50) | HTR2CNPC1RAB9AMEN1HPGD | |
| Hydrochloric Acid SCHEMBL11376323 | 0.91 | KDM4E (0.50) | HTR2CNPC1RAB9AMEN1HPGD | |
| Hydrochloric Acid SCHEMBL5629796 | 0.91 | KDM4E (0.50) | HTR2CNPC1RAB9AMEN1HPGD | |
| Pyridine SCHEMBL28843827 | 0.83 | PLD1 (0.44) | HTR2CNPC1RAB9ACHRNB2CHRNA4 | |
| SCHEMBL160290 | 0.83 | NPC1 (0.53) | NPC1RAB9AMEN1HPGDALDH1A1 | |
| SCHEMBL15058848 | 0.83 | — | — | |
| SCHEMBL28915046 | 0.82 | HTR2C (0.44) | HTR2CNPC1RAB9AMEN1HPGD | |
| SCHEMBL13711959 | 0.81 | NPC1 (0.51) | NPC1RAB9AMEN1HPGDALDH1A1 | |
| SCHEMBL233663 | 0.81 | NPC1 (0.51) | NPC1RAB9AMEN1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20220348577-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LLC (US) | 2022-11-03 | — | — | US | disclosed |
| US-10995091-B2 | CXCR4 receptor antagonists | PROXIMAGEN LLC (US) | 2021-05-04 | — | — | US | disclosed |
| US-10995091-B2 | CXCR4 receptor antagonists | PROXIMAGEN LLC (US) | 2021-05-04 | — | — | US | disclosed |
| US-10155761-B2 | CXCR4 receptor antagonists | PROXIMAGEN, LLC (US) | 2018-12-18 | — | — | US | disclosed |
| EP-2927224-B1 | Receptor antagonists | PROXIMAGEN LTD (GB) | 2018-10-03 | — | — | EP | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| EP-2627649-A1 | CXCR4 RECEPTOR ANTAGONISTS | Proximagen Limited (GB) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012049277-A1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-19 | — | — | WO | disclosed |
| US-7871999-B2 | Substituted thiazoles and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2011-01-18 | — | — | US | disclosed |
| EP-1968957-B1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| WO-2007079960-A9 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2008-10-23 | — | — | WO | disclosed |
| EP-1968957-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| WO-2007079960-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226106-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | HTR2C 678/4885NPC1 778/4885RAB9A 1677/4885 |
| US-20220348577-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | HTR2C 678/4885NPC1 778/4885RAB9A 1677/4885 |
| US-10155761-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | HTR2C 678/4885NPC1 778/4885RAB9A 1677/4885 |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR2C 4531/4885NPC1 3767/4885RAB9A 94/4885 |
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | TPMT, SLC5A2, DPP4 | HTR2C 1014/4885NPC1 871/4885RAB9A 4530/4885 |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | HTR2C 933/4885NPC1 1547/4885RAB9A 1259/4885 |
| US-10995091-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | HTR2C 678/4885NPC1 778/4885RAB9A 1677/4885 |
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | HTR2C 3853/4885NPC1 4530/4885RAB9A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.